CL2024001470A1 - Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica - Google Patents
Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónicaInfo
- Publication number
- CL2024001470A1 CL2024001470A1 CL2024001470A CL2024001470A CL2024001470A1 CL 2024001470 A1 CL2024001470 A1 CL 2024001470A1 CL 2024001470 A CL2024001470 A CL 2024001470A CL 2024001470 A CL2024001470 A CL 2024001470A CL 2024001470 A1 CL2024001470 A1 CL 2024001470A1
- Authority
- CL
- Chile
- Prior art keywords
- kidney disease
- chronic kidney
- treating chronic
- synthase inhibitors
- aldosterone synthase
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289177P | 2021-12-14 | 2021-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001470A1 true CL2024001470A1 (es) | 2024-09-13 |
Family
ID=85151059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001470A CL2024001470A1 (es) | 2021-12-14 | 2024-05-16 | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12263157B2 (https=) |
| EP (1) | EP4447961A1 (https=) |
| JP (1) | JP2025500826A (https=) |
| KR (1) | KR20240122521A (https=) |
| CN (1) | CN118401241A (https=) |
| AR (1) | AR127948A1 (https=) |
| AU (1) | AU2022415313A1 (https=) |
| CA (1) | CA3236890A1 (https=) |
| CL (1) | CL2024001470A1 (https=) |
| MX (1) | MX2024007335A (https=) |
| TW (1) | TW202339719A (https=) |
| WO (1) | WO2023114170A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019546A1 (en) * | 2023-07-17 | 2025-01-23 | Mineralys Therapeutics, Inc. | Methods of treating chronic kidney disease (ckd) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor |
| TW202525278A (zh) * | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
| US20250255851A1 (en) * | 2024-02-14 | 2025-08-14 | Boehringer Ingelheim International Gmbh | Solid forms of an aldosterone synthase inhibitor |
| WO2025190858A1 (en) * | 2024-03-12 | 2025-09-18 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitor for treating heart failure |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008959A1 (fr) | 1992-10-20 | 1994-04-28 | Taisho Pharmaceutical Co., Ltd. | Derive de prostaglandine |
| AU714033B2 (en) | 1996-07-19 | 1999-12-16 | Nissan Chemical Industries Ltd. | Method for producing purified epoxy compound |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| ZA200500918B (en) | 2002-10-15 | 2006-12-27 | Otsuka Pharma Co Ltd | 1-substituted 4-nitroimidazole compound and process for producing the same |
| CA2494710C (en) | 2002-10-15 | 2011-05-03 | Otsuka Pharmaceutical Co., Ltd. | 1-substituted-4-nitroimidazole compound and method for preparing the same |
| EP1996588A4 (en) | 2006-03-03 | 2011-10-05 | Torrent Pharmaceuticals Ltd | NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS |
| EP2001866A2 (en) | 2006-03-29 | 2008-12-17 | Novartis AG | Organic compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| JP2007297305A (ja) | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| CA2660701A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| WO2010016987A1 (en) | 2008-08-05 | 2010-02-11 | Dow Global Technologies Inc. | Production of solid epoxy resin |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| TW201026688A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Benzodioxan analogues as alpha2C adrenergic receptor modulators |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| CA2761009A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| NZ596302A (en) | 2009-05-15 | 2014-01-31 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| BR112012002214B1 (pt) | 2009-07-31 | 2022-01-25 | Global Alliance For Tb Drug Development | Análogos de nitroimidazooxazina e nitroimidazooxazol, seus usos e composição farmacêutica |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| HRP20192323T1 (hr) | 2011-09-15 | 2020-03-20 | F. Hoffmann - La Roche Ag | Novi derivati dihidrokinolin-2-ona |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| AR088989A1 (es) | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| HRP20171996T1 (hr) | 2012-04-17 | 2018-02-09 | F. Hoffmann - La Roche Ag | Novi derivati fenil-tetrahidroizokinolina |
| KR102096927B1 (ko) | 2012-09-04 | 2020-04-06 | 삼성전자주식회사 | 제어 채널 엘리먼트들에 대한 어그리게이션 레벨들 개수 조정 장치 및 방법 |
| CA2886117C (en) | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| US8912341B2 (en) | 2013-01-16 | 2014-12-16 | Northwestern University | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014168861A2 (en) | 2013-04-08 | 2014-10-16 | Cowans Kenneth W | Air supply concepts to improve efficiency of vcrc engines |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| JP6067181B2 (ja) | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| JP6471153B2 (ja) | 2013-10-17 | 2019-02-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体 |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| HUE039981T2 (hu) | 2014-07-24 | 2019-02-28 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
| WO2016061161A1 (en) | 2014-10-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| WO2016119706A1 (zh) | 2015-01-29 | 2016-08-04 | 南京明德新药研发股份有限公司 | 抗肺结核病的硝基咪唑衍生物 |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| KR20190084096A (ko) | 2016-11-10 | 2019-07-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 조성물, 치료 방법 및 이의 용도 |
| CN109053637B (zh) | 2018-08-14 | 2021-03-16 | 杭州泽旺生物科技有限公司 | 尺蠖类性信息素及其中间体的合成方法 |
-
2022
- 2022-12-13 TW TW111147688A patent/TW202339719A/zh unknown
- 2022-12-13 CA CA3236890A patent/CA3236890A1/en active Pending
- 2022-12-13 JP JP2024534762A patent/JP2025500826A/ja active Pending
- 2022-12-13 AR ARP220103413A patent/AR127948A1/es not_active Application Discontinuation
- 2022-12-13 CN CN202280082162.7A patent/CN118401241A/zh active Pending
- 2022-12-13 EP EP22850783.6A patent/EP4447961A1/en active Pending
- 2022-12-13 US US18/079,904 patent/US12263157B2/en active Active
- 2022-12-13 AU AU2022415313A patent/AU2022415313A1/en active Pending
- 2022-12-13 KR KR1020247023466A patent/KR20240122521A/ko active Pending
- 2022-12-13 WO PCT/US2022/052631 patent/WO2023114170A1/en not_active Ceased
- 2022-12-13 MX MX2024007335A patent/MX2024007335A/es unknown
-
2024
- 2024-05-16 CL CL2024001470A patent/CL2024001470A1/es unknown
- 2024-10-29 US US18/930,470 patent/US20250049763A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4447961A1 (en) | 2024-10-23 |
| US12263157B2 (en) | 2025-04-01 |
| AU2022415313A1 (en) | 2024-05-02 |
| US20250049763A1 (en) | 2025-02-13 |
| US20230181538A1 (en) | 2023-06-15 |
| JP2025500826A (ja) | 2025-01-15 |
| MX2024007335A (es) | 2024-06-26 |
| TW202339719A (zh) | 2023-10-16 |
| KR20240122521A (ko) | 2024-08-12 |
| CA3236890A1 (en) | 2023-06-22 |
| CN118401241A (zh) | 2024-07-26 |
| AR127948A1 (es) | 2024-03-13 |
| WO2023114170A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001470A1 (es) | Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica | |
| UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
| CL2025001072A1 (es) | Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. | |
| PY2126213A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| CL2024000593A1 (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento... | |
| CO6351738A2 (es) | Compuestos organicos | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| CR20250446A (es) | Inhibidores de prmt5 y usos de los mismos | |
| MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
| MX2024014401A (es) | Inhibidor de parp que es un derivado biciclico y uso de este | |
| ECSP21091203A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| MX2025002218A (es) | Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3 | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| DOP2025000212A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| AR127165A1 (es) | Resmetirom para reducir el volumen del hígado | |
| CL2024000114A1 (es) | Compuestos terapéuticos y procedimientos. | |
| CL2025002792A1 (es) | Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores | |
| AR127496A1 (es) | Compuestos de cd73 | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| UY40025A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far | |
| PY2189412A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis |